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ABSTRACT
Background: Diabetic patients are susceptible to developing foot ulcers with serious complications
such as osteomyelitis and amputations. Treatment approaches are still empirical and the benefit of
usual procedures such as surgical debridement has not been properly evaluated. Photodynamic
Therapy (PDT) is a non-invasive and highly efficient method for the treatment of the diabetic foot,
being able to eradicate the infection and to stimulate healing, decreasing considerably the amputa-
tion risk. In the day-to-day practice of our service, we have been faced with the question whether
debridement is necessary before PDT. In here, we designed a study to answer that question.
Methods: Patients were divided in two groups: In one of the groups (n = 17), debridement
was performed before PDT and in the other (n = 40) only PDT treatment was performed. PDT
sessions were performed once a week in all patients until healing was achieved, as indicated
by visual inspection as well as by radiographic and laboratory exams. At the start of the study,
the two groups had no statistical differences concerning their clinical features: average age,
gender, insulin use, diabetes mellitus onset time and previous amputations.
Results: PDT was effective in the treatment of 100% of the patients showing no relapses after
one year of follow up. The group submitted to PDT without previous debridement had a
statistically significant (p = 0.036, Mann-Whitney) shorter cure time (29 days, ~27%).
Conclusion: Our data indicates that debridement is not necessary in the treatment of diabetic
foot in patients that have enough peripheral arterial perfusion. In addition, we reproduced
previous studies confirming that PDT is an efficient, safe, simple and affordable treatment
method for the diabetic foot.
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Introduction
Osteomyelitis usually responds poorly to antimicrobial
therapy and infections starting in the toes can compro-
mise the entire foot structure. Gangrene and osteomyeli-
tis are two clinical situations with an indication for
amputation. The susceptibility of diabetic patients to
develop foot ulcers and osteomyelitis leads to a high
risk of lower limb amputations, which is around 15–70
times higher than in non-diabetic patients [1–4].
The current consensus is that immediate debridement
surgery is necessary as soon as the infection is clinically
diagnosed [5]. Series of debridement procedures, which
may be required to achieve complete cleaning of the
wound, can take the medical doctor to decide for ampu-
tation [4]. Therefore, debridement surgery and amputa-
tion are justified in order to save the patient. A typical
example is the transmetatarsal amputation, which leads
to the maintenance of plantar support allowing patients
to walk without crutches or artificial leg [1–6]. Although
being a recommended procedure, recent data and
literature reviews question this procedure with tendency
to disfavor its use in the treatment of the diabetic foot.
[7–9]
Photodynamic therapy (PDT) is a promising therapy
for the management of various types of tumors and
infecting diseases. The action mechanism of PDT is
based on the photo-activation of specific compounds,
called photosensitizers, which trigger cell death andmod-
ulate the immune response [10,11]. As an anti-microbial
therapy, PDT stands as a procedure that does not induce
microbial resistance [11]. Tardivo and collaborators have
shown that PDT can be very useful in the treatment of the
infected diabetic foot, avoiding amputation surgeries and
the indiscriminate use of antibiotics.Moreover, PDT is an
ambulatory procedure, involving a lot less costs com-
pared with treatment modalities that require hospitaliza-
tion [12–14]. It is important to mention that other non-
systemic treatment modalities with or without debride-
ment have also been shown to be effective in the treat-
ment of the diabetic foot [15,16].
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The purpose of this study is to evaluate the need
for debridement in patients with infected diabetic
foot treated with PDT. We compared clinical results
in two groups of patients: the group that underwent
ulcer debridement before PDT (debrided patients),
with the group that did not go through debridement
(non-debrided patients).
Materials and methods
Casuistry
The present study was performed as a controlled
clinical trial with 57 patients with infected diabetic
foot. All patients were treated in the Diabetic Foot
Ambulatory at Padre Anchieta Hospital, Faculdade
de Medicina ABC, from March 2011 to April 2015.
Patients were referred to the Diabetic Foot
Ambulatory by vascular surgeons. We included
patients with serious infected diabetic foot, grade III
in the Wagner classification and with high amputa-
tion risk. Most patients had confirmed osteomyelitis
diagnosis, as evaluated by clinical examination ‘probe
to bone’, X-rays and laboratory tests. Patients with
clinical signs of peripheral vascular insufficiency were
excluded from this study; because, in these cases,
revascularization must precede the PDT treatment
[17]. White blood cell count, ESR (erythrocyte sedi-
mentation rate), and CRP (C-reactive protein) were
also part of the initial evaluation procedure.
Patients were divided in two groups. The group of
non-debrided patients (NDP) consisted of 40 patients
referred directly to receive PDT treatment without
prior hospitalization and/or debridement. The con-
trol group was named debrided patients (DP) and
consisted of 17 patients that underwent debridement
treatment previous to PDT. Table 1 shows the main
clinical characteristics of the patients included in the
present study. The average age of all 57 patients was
59.5 years (±9.6). The time of diabetes mellitus (DM)
onset was 16.9 and 11.8 years in the DP and NDP
groups, respectively; 70% and 57% of the patients in
the DP and NPD groups, respectively, had insulin
dependence. Among all 57 patients, 41.3% (58.8% in
DP and 37.5% in NDP groups) had already had one
or more minor amputations, such as fingers or trans-
metatarsal amputations. All patients were informed
about the PDT treatment and signed the informed
consent form. The FMABC Ethics Committee, case
number 257/2010, approved this study.
PDT intervention protocol
PDT sessions were held once a week. Stock solutions
of the photosensitizers methylene blue and toluidine
blue (Labsynth, São Paulo, Brazil) were prepared at
the concentration of 1% (mass:mass). These solutions
presented maximum value of light absorption at
664 nm and 630 nm, respectively. All patients with
osteomyelitis received a (1:1) mixture of the photo-
sensitizer solutions, via fistulas or ulcers, using syr-
inges and catheters to enhance infiltration of the
photosensitizer in the infected area, to stain the tis-
sues and the infected bones. Dressings with dry gauze
and crepe bands were used to cover the lesions imme-
diately after PDT. In the intervals between the PDT
sessions, patients had their dressing changed daily.
Only sunflower oil was applied to the wounds. All
these procedures were performed in outpatient facil-
ities. Figure 1 illustrates the equipment and methods
used in the PDT treatment of the diabetic foot.
All patients were photographed at every session,
using a Sony Cyber-shot DSC-W310 digital camera
(Sony Corporation), to observe and to measure the
evolution of the treated areas. X-rays were performed
to evaluate bone lesions in the feet, at the beginning
and at the end of the treatment. A patient was dis-
charged from the treatment after several clinical signs
of cure, including ulcer healing, absence of clinical
signs of inflammation and infection, improvement in
laboratory tests and radiological improvement of the
bone lesion. Patients were followed for 1 year after
the PDT treatment, in order to evaluate any new
event on their feet.
All patients received daily systemic oral antibiotics,
1 g of ciprofloxacin and 900 mg of clindamycin dur-
ing the first 14 days of treatment. The main objective
of the use of systemic antibiotics was to avoid the
spread of the infection. PDT has local and non-sys-
temic action. Therefore, once the purulent secretions
stopped being produced in the wound, the systemic
antibiotics were suspended in order to preserve renal
function and to prevent the development of bacterial
resistance.
Two light sources were used. The first was a FR-
100 white halogen light source model (FASA Ind.
Com. Imp., São Paulo, Brazil), with optical fibers
1.0 and 1.5 mm in diameter and 1 m long. This
light source is a broadband emitter, whose spectrum
covers completely the visible range (400–725 nm)
with maximum at 560 nm and with at least 30% of
the spectral power in the biological window (visible
red with wavelengths above 600 nm). FR-100 was
calibrated using a spectrophotometer surface model
Table 1. Features of the two study groups: non-debrided
patients (NDP) and debrided patients (DP).
NDP DP Total cases
Average age (years) 58 61 59
Median age (years) 57 61 59
Male gender (%) 65 70.6 65.2
Female gender (%) 35 29.4 34.8
Insulin use (%) 57.5 70.6 65.2
Non-insulin use (%) 42.5 29.4 34.5
Average of diabetes mellitus onset (age) 11.8 16.9 13.2
Previous amputations (%) 37.5 58.8 41.3
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USB2000 (Ocean Optics, Florida, USA). Optical
fibers were introduced through external fistulas
immediately after staining the cavitary lesions by
infusion of the phenothiazine solutions. The ends of
the fibers were suitably covered with a clear PVC
film, previously washed with aqueous chlorhexidine
(Riohex, Farmacêutica Rioquímica LTDA, São José
do Rio Preto, SP). Irradiation dose was of 6 J/cm2
per fiber, for 10 minutes. This procedure was
repeated weekly. The second light source consisted
of a light-emitting diode (LED) array (GDE Genesis
LEDs Solutions Ind., São Paulo, Brazil) comprising
LEDs with maximum emission spectrum at 590 nm
and at 640 nm. Irradiation was performed at 50 mW
output power and dose of 30 J/cm2 for 10 minutes.
The LED source was always placed in contact with
the surface of the foot separated by a thin sheet of
transparent and sterile plastic or placed at a distance
of 3–5 cm from the irradiated surface.
Statistical analysis
Qualitative variables were described by absolute and
relative frequencies and quantitative values were
expressed as the mean and standard deviation or as
the median and range. Frequency comparisons
among groups were performed with chi-square test
or Fisher’s exact test. The distributions of quantitative
variables were defined using a nonparametric
Kolmogorov–Smirnov test and a Mann–Whitney
test was used to compare independent groups. To
verify the correlation between two quantitative
variables, it was used the Spearman correlation test.
In all analyzes, SPSS statistical software, version 17.0
(SPSS Inc, Illinois, USA) was used, and statistical
significance level of p < 0.05 was adopted in all
comparisons.
Results
From the 57 patients included in this study 40
received PDT treatment without any debridement
(NDP) and 17 were initially debrided to receive
PDT subsequently (DP). In order to check if the DP
and NDP study groups were comparable, we analyzed
the use of insulin, gender, previous amputations,
average age and the diagnostic time of DM, as
shown in Tables 1 and 2. Although, the average
time of diabetes in the DP group was a bit longer
than in the NDP group (16.9 years compared
11.5 years), there was no statistical difference between
these groups regarding the diabetes time. In fact,
there was no significant difference between the two
groups in any of the variables used to define the
patient conditions before the start of PDT (Table 2).
We must emphasize that the photodynamic effect
depends on oxygen and patients having peripheral
arterial disease (PAD) must be initially submitted to
a revascularization procedure before PDT [17].
Therefore, patients with severe PAD were excluded
from this study.
All patients were treated with PDT and had their
ulcers healed, i.e., remission of osteomyelitis was
observed in 100% of the cases in both DP and NDP
Methylene Blue
Toluidine Blue
a
b
c e
d f
Figure 1. Steps in the treatment of the diabetic foot by PDT. (a) Molecular structure of the photosensitizers methylene blue and
toluidine blue. A (1:1) mixture of two aqueous solutions containing each 1% (mass:mass) of the dyes was used in the
treatments. (b) The photosensitizer solutions were applied topically and also injected in the ulcers. (c) A broadband emitter
(400–725 nm, maximum at 560 nm) containing a white halogen light, was connected to optical fibers (1.0 or 1.5 mm), which
were covered with clear PVC films and introduced in the ulcer cavities to allow efficient illumination of the infected sites.
(d) Irradiation was performed weekly with a dose of 6 J/cm2. (e) Subsequently, a LED array with 590 nm and 640 nm centered
LEDs was used to illuminate the surface of the infected sites. (f) Irradiations were performed either in close proximity to the
lesion or 3–5 cm away from the feet always with a dose of 30 J/cm2. For further details please refer to the Methods section.
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groups. Figure 2 shows two typical cases. Complete
bone reconstruction was observed through radiologi-
cal images, as shown in Figure 2. In many cases, there
was formation of bone callus in regions that had
previously suffered fractures or lysis of bones
(Figure 3). No patient had adverse reactions from
PDT [12,13,17].
Table 3 shows that the healing time after PDT varied
significantly between the two groups. Patients in the DP
group took an average of 135 ± 67 days for healing,
while in theNDP group 106 ± 77 days. The difference in
healing time was statistically significant (p = 0.036). An
amputation occurred in the group of patients who
underwent debridement before treatment with PDT,
but it represented just one case (Table 3). Clearly,
PDT performed better with faster healing time
(29 days shorter) in patients of the NDP group.
Statistical analyzes (Spearman’s correlation test) show
no correlation between the time required for treatment
versus the previous diabetic period (r = 0.177,
p = 0.206); nor between treatment time versus number
of amputations (r = 0.103, p = 0.444), nor there is
correlation between the time of diabetes versus the
number of amputations (r = 0.221; p = 0.111).
Therefore, we can only attribute the 27% increase in
the healing time to the initial debridement procedure.
Discussion and conclusions
Patients that live in regions with poor health care
system have more risks of complications from the
classic debridement procedure, such as infections
and general worsening of prognosis. The group of
patients who previously suffered debridement
required an average of 29 extra days to cure
(Table 3), compared with the group that went directly
Table 2. Statistical comparison between DP and NDP groups before PDT treatment.
Variables Total (n = 57) DP (n = 17) NDP (n = 40) p (test)
Insulin use 35/56 (62.5%) 12/17 (70.6%) 23/39 (59.0%) 0.551 (Fisher’s exact)
Male gender 38/57 (66.7%) 12/17 (70.6%) 26/40 (65.0%) 0.766 (Fisher’s exact)
Amputations 24/57 (42.1%) 9/17 (52.9%) 15/40 (37.5%) 0.280 (chi square)
Age (years) 59.5 ± 9.6 61.1 ± 9.6 58.6 ± 9.6 0.427 (Mann–Whitney)
DM (ages) 13.2 ± 8.6 16.9 ± 10.0 11.6 ± 7.5 0.066 (Mann–Whitney)
DM, diabetes mellitus.
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Figure 2. Images of patients before and after PDT. (a, b) Patient from the NDP group, was treated for 62 days to complete
healing (28/04–29/06). (c, d) Patient from the DP group, had his lesion healed in 125 days (08/12–14/04).
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to PDT. Therefore, sparing debridement procedure in
diabetic patients undergoing PDT will shorten the
healing period. The quicker treatment of the diabetic
foot results in better outcome for the patient, lower
involved costs, and possibly lower risks of amputation.
Although these results were obtained with a highly
efficient antimicrobial intervention (PDT), it is likely that
the debridement procedure may not be recommended
for any patient with reasonable peripheral blood perfu-
sion that is being treated with any local antimicrobial
intervention.12,17 This is in agreement with recent litera-
ture data that disfavor debridement in the treatment of
the diabetic foot in comparison with other procedures
[8,9]. Our work was based in a controlled study group,
with photographic and radiographic follow up for over
one year.We hope this data can provide support to justify
a larger non-randomized double blind clinical trial.
Diabetic patients with osteomyelitis, without signs of
ischemia have excellent chances of cure with PDT, with-
out the need of amputation or of extensive debridement
procedures. PDT confirmed to be a safe and low-cost
outpatient treatment, showing effective results for the
treatment of the diabetic foot.
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Figure 3. Osteomyelitis before and after PDT. X-Ray images obtained from patients with osteomyelitis before and after PDT
treatment. A, B, C, and D are X-ray images from four patients treated with PDT. Arrows at left are showing osteomyelitis in
metatarsal and phalanges before treatment with cortical disruption and pathological destruction or disappearance of bone
tissue. Arrows at right represent the same patients after PDT. Note the effective regeneration of diseased bones after PDT. A and
B were obtained from patients of the DP group, C and D from the NDP group.
Table 3. Statistical comparison between DP and NDP groups after PDT treatment.
Variables Total (n = 57) DP (n = 17) NDP (n = 40) p (test)
Time of PDT (days) 114.5 ± 74.5 135.1 ± 66.7 105.8 ± 76.7 0.036 (Mann–Whitney)
Number of amputations (median; amplitude) 0 (0–3) 1 (0–3) 0 (0–3) 0.429 (Mann–Whitney)
PDT, photodynamic therapy.
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